Kurs
-6,25%
Likviditet
0,05 MSEK
Kalender
Tid* | ||
2025-05-06 | N/A | Årsstämma |
2025-02-12 | 12:00 | Bokslutskommuniké 2024 |
2024-11-07 | - | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-07-30 | - | Split QLIFE 2000:1 |
2024-05-28 | - | Kvartalsrapport 2024-Q1 |
2024-05-08 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
2024-05-07 | - | Årsstämma |
2024-02-08 | - | Bokslutskommuniké 2023 |
2024-01-16 | - | Extra Bolagsstämma 2023 |
2023-11-13 | - | Kvartalsrapport 2023-Q3 |
2023-08-17 | - | Kvartalsrapport 2023-Q2 |
2023-05-26 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
2023-05-04 | - | Årsstämma |
2023-03-24 | - | Extra Bolagsstämma 2022 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-25 | - | Kvartalsrapport 2022-Q3 |
2022-08-29 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
2022-05-05 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-08 | - | Kvartalsrapport 2021-Q3 |
2021-08-16 | - | Kvartalsrapport 2021-Q2 |
2021-05-06 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
2021-05-05 | - | Årsstämma |
2021-05-05 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Extra Bolagsstämma 2020 |
2020-11-18 | - | Kvartalsrapport 2020-Q3 |
2020-08-18 | - | Kvartalsrapport 2020-Q2 |
2020-05-22 | - | X-dag ordinarie utdelning QLIFE 0.00 SEK |
2020-05-20 | - | Årsstämma |
2020-05-20 | - | Kvartalsrapport 2020-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Qlife Holding AB (publ) ("Qlife" or the "Company") has decided to withdraw its proposal to change the Company's name as the intended name, Egoo Health AB, cannot be registered by the Swedish Companies Registration Office (Bolagsverket).
On 29 August 2024, Qlife announced its intention to change the Company's name to Egoo Health AB as part of a broader rebranding initiative. However, the Swedish Companies Registration Office has informed the Company that Egoo Health AB cannot be registered. As a result, Qlife has decided to withdraw the proposal to change its name.
The Company remains fully dedicated to its business strategy and operations. This decision will have no impact on its operations, nor on its relationships with customers, partners, or stakeholders.
"It was not possible to streamline into one name, however it won't have any effect on the positive journey we have started in the rare disease field with launch of our PHE test and with our continued focus on advancing our effort in China", says Thomas Warthoe CEO of Qlife.
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34